MaxCyte, Inc. (MXCT) stock

MXCTNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3062% below fair value

$1.19+0.09 (+8.18%)

Close on Nov 12, 2026Market cap $122.82MP/E –Yield –

MaxCyte revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

MaxCyte's revenue for the twelve months ending Sep 30, 2026 was $34.37M, down 0.1% year over year. For fiscal 2025 it was $33.03M, down 14.5% from the year before. The highest annual figure on record is $44.26M in fiscal 2022.

Annual revenue

Period	Period end	Value	Change
FY2025	Dec 31, 2025	$33.03M	-14.5%
FY2024	Dec 31, 2024	$38.63M	-6.4%
FY2023	Dec 31, 2023	$41.29M	-6.7%
FY2022	Dec 31, 2022	$44.26M	+30.6%
FY2021	Dec 31, 2021	$33.89M	+29.5%
FY2020	Dec 31, 2020	$26.17M	+21.0%
FY2019	Dec 31, 2019	$21.62M	–

Quarterly revenue

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q3 FY2026	Sep 30, 2026	$10.15M	+48.7%
Q2 FY2026	Jun 30, 2026	$7.27M	-14.5%
Q1 FY2026	Mar 31, 2026	$9.65M	-7.1%
Q4 FY2025	Dec 31, 2025	$7.30M	-16.0%
Q3 FY2025	Sep 30, 2025	$6.83M	-16.4%
Q2 FY2025	Jun 30, 2025	$8.51M	-18.4%
Q1 FY2025	Mar 31, 2025	$10.39M	-8.4%
Q4 FY2024	Dec 31, 2024	$8.69M	-44.5%
Q3 FY2024	Sep 30, 2024	$8.16M	+2.0%
Q2 FY2024	Jun 30, 2024	$10.43M	+15.3%
Q1 FY2024	Mar 31, 2024	$11.34M	+32.3%
Q4 FY2023	Dec 31, 2023	$15.67M	+26.1%
Q3 FY2023	Sep 30, 2023	$8.00M	-24.8%
Q2 FY2023	Jun 30, 2023	$9.04M	-5.9%
Q1 FY2023	Mar 31, 2023	$8.58M	-26.0%
Q4 FY2022	Dec 31, 2022	$12.42M	+22.4%
Q3 FY2022	Sep 30, 2022	$10.64M	+5.0%
Q2 FY2022	Jun 30, 2022	$9.61M	+35.2%
Q1 FY2022	Mar 31, 2022	$11.59M	+78.4%
Q4 FY2021	Dec 31, 2021	$10.15M	+19.2%
Q3 FY2021	Sep 30, 2021	$10.14M	+49.9%
Q2 FY2021	Jun 30, 2021	$7.11M	+38.0%
Q1 FY2021	Mar 31, 2021	$6.49M	–
Q4 FY2020	Dec 31, 2020	$8.51M	–
Q3 FY2020	Sep 30, 2020	$6.76M	–
Q2 FY2020	Jun 30, 2020	$5.15M	–